Trial to Determine Effective Aspirin Dose in COPD
NCT05265299
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States. Current treatments for COPD focus on inhaler therapies that do not address manifestations of the disease on other organ systems. Platelets, which are small blood cells that typically help with clotting, are also involved in generalized inflammation and dysfunctionality of immune cells when these cells become activated. Activated platelets have long been known to play a role in the development of cardiovascular disease.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Pulmonary Disease, Chronic Obstructive
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Johns Hopkins University
- Last updated on ClinicalTrials.gov
- March 16, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- Johns Hopkins Bayview Medical Center · Baltimore, MD
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.